April 30, 2024 News by Andrea Lobo, PhD Nektar to develop NKTR-0165 for MS, autoimmune diseases NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by Nektar Therapeutics as a candidate for treating multiple sclerosis (MS) and other autoimmune diseases. The experimental therapy was developed under a 2021 collaboration between Nektar and Biolojic…
April 29, 2024 Columns by Leigh Anne Nelson My biggest worry post-diagnosis was whether MS could be inherited When I was initially evaluated for multiple sclerosis (MS), I was asked if I had a family history of the disease. To my knowledge, I did not. Once I received my diagnosis, one of the first things that crossed my mind, after recovering from the initial shock…
April 29, 2024 News by Lindsey Shapiro, PhD Specialized PET scan shows chronic inflammation tied to MS progression A specialized imaging approach was able to detect signs of persistent inflammation in the brains of people with multiple sclerosis (MS) that aren’t readily captured by standard MRI scans. This so-called smoldering inflammation was also observed among those patients taking high-efficacy disease-modifying therapies (DMTs), where a higher degree…
April 29, 2024 News by Marisa Wexler, MS Lower vidofludimus calcium dose not as effective in RRMS trial A lower dose of the experimental oral therapy vidofludimus calcium (IMU-838) was not as effective as higher doses at reducing lesions in people with relapsing-remitting multiple sclerosis (RRMS), extended data from the therapy’s Phase 2 EMPhASIS trial show. “We found that doses of 30 mg and 45 mg,…